CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients
with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained …

For approximately three decades, autologous hematopoietic cell transplantation (auto-HCT)
has been the standard of care for patients with relapsed/refractory (R/R) diffuse large B-cell …

Despite the success of CD19-targeted chimeric antigen receptor (CAR T)-cell therapy in
patients with relapsed/refractory large B-cell lymphoma (LBCL), there is a need for effective …

The prognosis of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
(DLBCL) is poor. Chimeric antigen receptor (CAR) T-cell therapy has been approved for R/R …

CD19-targeted chimeric antigen receptor T (CAR T) cell therapy is a promising option to
treat relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). However, the majority …

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment
with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We …

Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …

Background: CD19-targeted chimeric antigen receptor T cell (CAR T) therapies have
remarkable overall response rates (ORR) for relapsed diffuse large B cell lymphoma …

Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) have a poor
prognosis. Chimeric antigen receptor (CAR) modified T cells targeting CD19 hold great …

Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-
cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion …